Sanofi Opens New Framingham Bio-Manufacturing Site
Council member Sanofi opened the doors of its 100,000 square foot digital bio-manufacturing facility in Framingham, MA, on October 15, 2019. The French drug manufacturing company is one of Massachusetts’ largest life science employers.
Sanofi’s new facility is among the first digitally-enabled continuous manufacturing sites, making the building itself about a fifth the size of traditional facilities. The new building features state-of-the-art technology that connects the production process with research and development to better improve the commercialization of important medicines. The acceleration of their production capabilities is a key pillar in Sanofi’s ambition to establish “the gold standard in the bio-pharmaceutical industry.”
“We have been investing for some years to prepare for Sanofi’s future. Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi. “This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry.”
The Council congratulates Sanofi on this new state-of-the-art facility and wishes them continued growth and success.